Definitive Contract 75N93019C00056

Award Date 9/9/19
Potential Completion Date 1/31/26
Potential Value $29M
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Boulder, CO 80301, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed

This is a $28,613,040.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Crestone, Inc., a biotech company specializing in research on treatments for antibiotic-resistant bacterial infections. The contract supports Crestone's work to synthesize antibiotic compounds, test their activity, and advance lead candidates through investigational new drug filing and early clinical trials. This includes research on treatments for Clostridioides difficile and other threats identified by the Centers for Disease Control and Prevention. The contract was awarded on a non-set-aside basis and will run through January 31, 2026. Crestone has also received previous federal contracts and grants from NIAID and the Department of Veterans Affairs to fund its work in this area.

Generated 12/4/24, 10:07 AM